The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•25 June 2026•

1 min read

Addex Therapeutics Reports CHF 1.7M Net Loss in Q1 2026

Key Facts

1Addex Therapeutics reported a net loss of CHF 1.7 million for the first quarter of 2026.

Addex Therapeutics reported a net loss of CHF 1.7 million for the first quarter of 2026, as part of its regular quarterly financial update. The report also provided progress on its spin-out Neurosterix and the lead candidate NTX-253 (M4 PAM) currently in Phase 1 development for schizophrenia.

Addex's net loss in Q4 2025 was CHF 2.1 million, indicating a modest improvement. Cash and cash equivalents at the end of Q1 2026 stood at approximately CHF 8.5 million, providing a cash runway to support ongoing development of NTX-253 and other activities. While no near-term catalysts are expected, the Phase 1 progress of NTX-253 remains a key focus for investors.

Sources: